Gut bacteria and liver cirrhosis study
Part of Digestive system clinical trials.
This study looks at how gut bacteria change in people with liver cirrhosis and whether these changes relate to how the disease progresses. It may help find new ways to monitor or treat cirrhosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are healthy with no liver disease, or you have been diagnosed with liver cirrhosis for more than 6 months.
- Your cirrhosis may be caused by hepatitis B, fatty liver disease, or alcohol use.
- You are willing to participate and sign a consent form.
- You do not have other severe organ diseases, cancer, or autoimmune conditions.
- You have not had an acute infection or inflammation in the past month.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is exploring a new way to predict how liver cirrhosis will progress. It may help doctors better understand and manage the condition.
This trial is looking at bacteria inside the liver of people with alcoholic hepatitis. It may help understand how these bacteria affect the disease and lead to better treatments.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at how nutrition affects the health of people with liver cirrhosis (scarred liver) and aims to build a tool to predict their outcomes. If you have cirrhosis, joining may help researchers find better ways to support your health.
This study looks at bacterial infections in people with cirrhosis to understand which antibiotics still work. The goal is to improve treatment for future patients with liver disease.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and the chemicals it makes are linked to a type of fatty liver disease called MAFLD. By joining, you'll help researchers understand this connection, which may lead to better treatments in the future.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.